Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Spruce Biosciences
This is a Phase 2 open-label study with up to 10 cohorts that will evaluate the safety, efficacy, and PK of different tildacerfont dosing regimens potentially up to 200mg QD for 12 weeks in children with classic CAH, and up to 400mg BID for 4 weeks in children and adults with classic CAH.
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female subjects aged 2+
Diagnosis of CAH due to 21-hydroxylase deficiency (OHD) and/or elevated 17- hydroxyprogesterone (OHP) requiring ongoing GC replacement since diagnosis
Stable dose of GC replacement for at least 1 month prior to screening
You may not be if
History of bilateral adrenalectomy or hypopituitarism
Clinically significant unstable medical conditions, illness, or chronic diseases
